What the Tirzepatide Package Insert Really Tells You (and What It Doesn't)

The biggest misconception: the SmPC is a document for patients

People sometimes search for a tirzepatide "package insert" expecting a plain-English leaflet they can follow. The SmPC is actually a technical document written for prescribers and pharmacists, dense with clinical pharmacology, pharmacokinetic data and regulatory language. The document you actually receive with your pen is the Patient Information Leaflet (PIL), a shorter, plainer companion required by UK law. Both are produced by Eli Lilly and reviewed by the MHRA; both carry the same factual content, just pitched at different audiences.

That distinction matters because a line in the SmPC about titration timing is aimed at a clinician interpreting your whole picture, your kidney function, your other medicines, your GI history. Reading it without that context can make the document feel alarming or confusing in equal measure. The Mounjaro overview page translates the key facts into plain English, which is a more useful starting point for most people.

With that said, the SmPC is genuinely worth knowing exists. It is freely available, publicly searchable, and it is the authoritative source for everything from licensed indications to shelf-life. If you ever want to verify a claim you have read elsewhere about tirzepatide, the eMC is where to start.

What the licensed indications and eligibility section actually says

The SmPC confirms that tirzepatide (Mounjaro) is licensed in the UK for two distinct uses: weight management in adults, and the treatment of type 2 diabetes. For weight management, the licensed population is adults with a body mass index of 30 kg/m² or above, or adults with a BMI from 27 kg/m² upward who have at least one weight-related condition, for example, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. The medicine carries a Black Triangle (▼) designation, meaning the MHRA requires additional post-marketing monitoring while the evidence base matures.

NICE's technology appraisal TA1026 (which informed how tirzepatide reaches NHS patients) works from the same population data, though with stricter commissioning thresholds than the licensed indications alone. Private eligibility via a regulated online pharmacy follows the SmPC criteria, with a prescriber making the final call based on your individual circumstances. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. The tirzepatide and age eligibility page covers the age-related detail the SmPC addresses separately.

One thing the SmPC does not contain is a guarantee of results for any individual. The clinical trial averages it cites are population statistics. Your prescriber uses them to inform the conversation, not to make a promise.

Safety information, contraindications and precautions in the prescribing document

The safety section of the SmPC is the part a prescriber reads most carefully before writing a prescription. It lists conditions where tirzepatide should not be used, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, and hypersensitivity to the active substance or any excipient. A history of pancreatitis also calls for careful assessment; the MHRA issued a Drug Safety Update in January 2026 reinforcing that severe and persistent stomach pain, particularly if it radiates to the back, warrants urgent medical attention.

The document also flags the interaction with oral contraceptives. Women using the pill are advised to add a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying and may reduce how much of the pill is absorbed. This is the kind of practical detail that a prescriber raises during a consultation; it is not a reason to avoid treatment, but it does need managing. If you want to understand exactly what arrives when your treatment is dispatched, our guide to Mounjaro packaging walks through what to expect when your treatment arrives.

The SmPC also notes that tirzepatide is not recommended in pregnancy, while breastfeeding, or for anyone under 18, as safety and efficacy have not been established in those groups. These are hard stops in the prescribing document, not caveats.

What the SmPC says about doses, pens and storage

Tirzepatide is available in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each pre-filled KwikPen contains four doses, meaning one pen covers four weekly injections. Treatment opens at the 2.5 mg strength (a dose whose job is to let your body adjust rather than produce maximum effect) and is increased in steps by the prescriber, typically every four weeks, based on tolerability and response. The tirzepatide information page covers the clinical rationale for this escalation in plain terms.

Storage is addressed precisely in the SmPC: the pen should be kept refrigerated between 2°C and 8°C. There is a defined window during which it can be stored at room temperature, but the exact duration changes between product versions and is one detail where the current leaflet inside the box should always be the reference, not a summary from any secondary source, including this page. Injection sites are the abdomen, thigh or upper arm; rotate between sites to reduce local reactions.

The SmPC is not the place to find cost information. For context on private treatment pricing in the UK, the cost and value guide covers what drives the price variation you see between providers. If you are considering starting treatment, a free consultation with our prescribers is the right first step, they review your information the same day, and every decision follows the prescribing document exactly.